Advertisement
Advertisement
U.S. markets close in 2 hours 1 minute
Advertisement
Advertisement
Advertisement
Advertisement

Avricore Health Inc (8VP1.SG)

Stuttgart - Stuttgart Delayed Price. Currency in EUR
0.2460+0.0140 (+6.03%)
As of 07:11PM CET. Market open.
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.2320
Open0.2300
Bid0.2260 x 0
Ask0.2460 x 0
Day's Range0.2300 - 0.2460
52 Week Range0.0455 - 0.2760
Volume18,000
Avg. Volume390
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateNov 29, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for 8VP1.SG

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • News Direct

      Avricore Health looks to continue positive growth in 2023 after success in 2022

      Avricore Health CEO Hector Bremner joined Proactive's Steve Darling with an update on the company's 2022 performance and the goals it has set for 2023.

    • GlobeNewswire

      Avricore Health Corporate Update – Earnings Advisory 2022 and 2023 Objectives

      VANCOUVER, British Columbia, Feb. 01, 2023 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or “AVCR”) is entering the second year of a multi-year growth plan to bring HealthTab, its turnkey solution for point of care testing and data management, to more pharmacies across Canada and the world. As part of this effort the Company is pleased to provide insight into the successes of last year and lay out updates and objectives on further progress. “Last year we set out bold targe

    • GlobeNewswire

      Avricore Health Reports Third-Quarter 2022 Results

      VANCOUVER, British Columbia, Nov. 29, 2022 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or “AVCR”) today released its Q3 results which demonstrate significant revenue growth, indicating it can scale sustainably and deliver on its long-term objectives. The Company’s objective to create the world’s first cloud-connected point-of-care network in community pharmacy is on track to becoming a reality, bringing powerful health screening and data management tools to community pha

    Advertisement
    Advertisement